Drug Profile
Research programme: vaccines - Panacea Biotec
Alternative Names: 13-Valent pneumococcal vaccine - Panacea Biotec; 15-Valent pneumococcal vaccine - Panacea Biotec; Dengue vaccine - Panacea Biotec; DTaP - Panacea Biotec; DTaP-HIB-TT-HepB-IPV - Panacea Biotec; DTaP-HIB-TT-IPV - Panacea Biotec; Hapy3; Hapyfive; Hapysix; Inactivated JEV vaccine - Panacea Biotec; Influenza virus vaccine universal - Panacea Biotec; Japanese encephalitis vaccine - Panacea Biotec; Live-attenuated dengue vaccine - Panacea Biotec; Measles vaccine - Panacea Biotec; Meninogococcal vaccine - Panacea Biotec; Neisseria meningitidis vaccine tetravalent - Panacea Biotec; Pneumococcal conjugate CRM vaccine; rDen-delta-30 NIH vaccine - Panacea Biotec; Recombinant influenza virus vaccine universal - Panacea Biotec; Recombinant tetravalent dengue vaccine - Panacea Biotec; Tetravalent meningococcal vaccine - Panacea Biotec; Universal influenza virus vaccine - Panacea BiotecLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Panacea Biotec; PT Bio Farma
- Developer Panacea Biotec
- Class Bacterial vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pneumococcal infections
Highest Development Phases
- No development reported Dengue; Influenza virus infections; Japanese encephalitis; Measles; Meningococcal infections; Pneumococcal infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Japanese encephalitis in India (IM, Injection)
- 23 Nov 2021 Preclinical trials in Japanese encephalitis ongoing in India (IM) (BioNet-Asia pipeline, November 2021)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Dengue in India (IM, Injection)